Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Inclusion Criteria:

• Completed an Addex randomized controlled study of dipraglurant and, in the judgementof the Investigator, may benefit from open-label treatment

• Able to take study drug 3 times daily and no less than 3 hours apart

• Must be taking levodopa not less than 3 times daily throughout the study

• Must maintain stable regimen of antiparkinson's medications (including levodopa) andbe willing to continue the same doses and regimens for the first 4 weeks of thestudy

Exclusion Criteria:

• Patient is judged by the Investigator to be inappropriate for the study (for reasonssuch as, but not limited to, significant noncompliance in the Addex randomizedcontrolled study of dipraglurant)

• Use of amantadine or amantadine ER throughout the study

• Use of memantine throughout the study

• Any use of marijuana or other cannabis/cannabinoid products for the first 4 weeks ofstudy participation

Other protocol-defined inclusion and exclusion criteria may apply